-+ 0.00%
-+ 0.00%
-+ 0.00%

Stifel Maintains Buy on AnaptysBio, Raises Price Target to $85

Benzinga·03/05/2026 12:05:19
Listen to the news
Stifel analyst Alex Thompson maintains AnaptysBio (NASDAQ:ANAB) with a Buy and raises the price target from $56 to $85.